Advanced-stage lung squamous cell carcinoma (LUSC) remains a therapeutic challenge. Although immune checkpoint inhibitors (ICIs) have revolutionized LUSC treatment, only a small subset of LUSC patients can achieve durable clinical benefits, underscoring the need for novel strategies. Emerging immunotherapy strategies have demonstrated early evidence of promise for LUSC patients, particularly multi-specific antibodies and fusion proteins, antibody-drug conjugates, adoptive cell therapies,…
Emerging Options and Future Strategies in Immunotherapy for Advanced Lung Squamous Cell Carcinoma
Annals of Oncology | | Y. Wang, R. Rosell, F.R. Hirsch, S. Lu, R. Govindan, K. Park, S. Peters, J.J. Zhang
Topics: blood-cancer, cervical-cancer, immunotherapy, targeted-therapy, new-technology, research